Baseline characteristics of the Systemic Lupus International Collaborating Clinics cohort at entry to the study
Number of patients | 1722 |
Age, years | 35.0 (S.D. 13.4) |
Gender | |
Female | 1536 (89.2) |
Male | 186 (10.8) |
Enrolment location | |
Canada | 398 (23.1) |
USA | 497 (28.9) |
Mexico | 212 (12.3) |
Europe | 446 (25.9) |
Asia | 169 (9.8) |
Race/ethnicity | |
Caucasian | 830 (48.2) |
Hispanic | 268 (15.6) |
Asian | 271 (15.7) |
African origin | 280 (16.3) |
Other | 71 (4.1) |
Disease phenotype at baseline | |
SLEDAI-2K | 5.3 (5.3)* |
Active renal disease | 467 (27.1) |
Thrombocytopenia (platelet count <100 000) | 47 (2.7) |
Medication use | |
Oral corticosteroids (CS) | 1199 (69.6) |
Average CS dose (mg/day) | 24.1 (16.7)* |
Highest CS dose (mg/day) | 43.5 (74.3)* |
Immunosuppressants | 684 (39.7) |
Antimalarials | 1153 (67) |
Co-morbidities | |
Systolic blood pressure (mm Hg) | 119.5 (16.8)* |
Diastolic blood pressure (mm Hg) | 75.1 (11.1)* |
Taking antihypertensives | 505 (29.3) |
Diabetes mellitus | 60 (3.5) |
Current smoker | 263 (15.3) |
Post-menopausal | 162 (9.4) |
Body mass index (kg/m2) | 25.2 (5.9)* |
Baseline serology | |
Anti-dsDNA positive | 663 (38.5) |
Low C3 and/or C4 complement | 586 (34.0) |
Anti-B2-GPI positive | 241 (14) |
Anti-cardiolipin positive | 133 (7.7) |
Lupus anticoagulant positive | 208 (12.1) |
*All data are n (%) of patients or mean (SD) where indicated.
SLEDAI-2K, Systemic Lupus Erythematosus Disease Activity Index 2000.